The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments.Â
MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).
Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.
CEO Rohan Greenland reflects on May, a significant month for the MS community, highlighting the launch of the MS Nurse-led Back on Track resource, the Foundations of MS Nursing Course and the success of The May 50K.
Tessa was 16 when she first experienced symptoms of MS. Over three decades later, she’s sharing her lived experience in a memoir: ‘Flying Solo’. Tessa explores the events that have shaped her life, shares her many travel adventures and the realities of living with MS.
A new international study found children with MS who started highly effective treatment before age 18 had less disability in early adulthood than those starting later.
Researchers have found that children and young people with childhood-onset MS ate more ultra-processed foods than same-aged people without MS.
New research shows that in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), smoking is associated with relapse rates more than twice that of those who had never smoked.
Living with MS and incontinence can be challenging, but it is also manageable with the right support, planning and practical strategies. We asked MS Australia’s Lived Experience Expert Panel (LEEP) about the ups and downs, and their top tips for managing this invisible symptom of MS.
